2024. Bimekizumab Continuous Maintenance of Eesponse at Every Visit Through Two Years in Patients with Moderate to Severe Plaque Psoriasis: Post-hoc Results from Five Phase 3/3b Trials. SKIN The Journal of Cutaneous Medicine. 8, 1 (Jan. 2024), s303. DOI:https://doi.org/10.25251/skin.8.supp.303.